IR-Med, Inc. Files for IPO

TL;DR

IR-Med, Inc. (formerly Int'l Display Adv) just filed for IPO, aiming to list on the public market.

AI Summary

IR-Med, Inc. filed an S-1 form on June 24, 2024, indicating its intention to go public. The company, formerly known as International Display Advertising, Inc. until January 5, 2021, is incorporated in Nevada and operates in the electromedical and electrotherapeutic apparatus sector. Its business and mailing address are located at 745 5th Ave, Suite 500, New York, NY 10151.

Why It Matters

This S-1 filing signals IR-Med, Inc.'s move towards becoming a publicly traded company, which could lead to increased capital for expansion and innovation in the electromedical sector.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company in the process of going public, which inherently carries risks associated with market reception and operational scaling.

Key Numbers

• 333-280446 — SEC File Number (Identifies the specific SEC registration for IR-Med, Inc.)
• 0001839133 — Central Index Key (CIK) (Unique identifier for IR-Med, Inc. in SEC filings.)

Key Players & Entities

• IR-Med, Inc. (company) — Filer of the S-1 document
• International Display Advertising, Inc. (company) — Former name of IR-Med, Inc.
• 20210105 (date) — Date of name change from International Display Advertising, Inc. to IR-Med, Inc.
• 20240624 (date) — Filing date of the S-1 document
• 745 5th Ave, Suite 500, New York, NY 10151 (address) — Business and mailing address of IR-Med, Inc.

FAQ

Key Financial Figures

• $0.001 — of one share of common stock, par value $0.001 per share, and one warrant to purchase
• $0.60 — mmon stock as reported on the OTCQB was $0.60 per share. We intend to apply to list o
• $26.8 billion — ssue. PIs in the U.S. alone account for $26.8 billion in healthcare spending and result in 60
• $10.2 billion — and Quality (AHRQ) reports that PIs add $10.2 billion to annual U.S. healthcare costs. Furthe
• $26.8 b — utable to hospital-acquired PIs reaches $26.8 billion, and 2.5 million patients per yea
• $20,900 — I. Patient care costs per PI range from $20,900 up to $151,700. PIs are among one of th
• $151,700 — e costs per PI range from $20,900 up to $151,700. PIs are among one of the five most com
• $250,000 — Is annually at an average settlement of $250,000. PIs occur across the healthcare indust
• $10.2 Billion — 9. Pressure Ulcers Cost U.S. Healthcare $10.2 Billion and Contribute to Nearly 29,000 Hospita
• $645 billion — arket, which is anticipated to be worth $645 billion by 2025 (CAGR 8.7%). 7 It is estimated
• $645.10 billion — Market will grow at CAGR of 8.7% to hit $645.10 billion by 2025 : Adroit Market Research. 8 F

Filing Documents

• forms-1.htm (S-1) — 2650KB
• ex4-2.htm (EX-4.2) — 18KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 23KB
• forms-1_001.jpg (GRAPHIC) — 39KB
• forms-1_002.jpg (GRAPHIC) — 21KB
• forms-1_003.jpg (GRAPHIC) — 4KB
• form10-ka_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-024999.txt ( ) — 8796KB
• irme-20240331.xsd (EX-101.SCH) — 51KB
• irme-20240331_cal.xml (EX-101.CAL) — 65KB
• irme-20240331_def.xml (EX-101.DEF) — 196KB
• irme-20240331_lab.xml (EX-101.LAB) — 322KB
• irme-20240331_pre.xml (EX-101.PRE) — 292KB
• forms-1_htm.xml (XML) — 1353KB

Risk Factors

Risk Factors 21 Cautionary Note Regarding Forward-Looking Statements 49 Market And Industry Data 50

Use Of Proceeds

Use Of Proceeds 51 Dividend Policy 52 Capitalization 53

Management's Discussion and Analysis of Financial Condition And Results Of Operations

Management's Discussion and Analysis of Financial Condition And Results Of Operations 54

Business

Business 63 Management 80 Executive And Director Compensation 85 Certain Relationships and Related Party Transactions 92 Principal Stockholders 93 Determination of Offering Price 94 Description of the Securities 95 Shares Eligible for Future Sale 99 Material U.S. Federal Income Tax Considerations 100

Underwriting

Underwriting 108 Legal Matters 114 Experts 115 Where You Can Find Additional Information 116 Index To Consolidated Financial Statements F-1 Information Not Required In Prospectus II-1

Signatures

Signatures II-5 2 Neither we nor the Underwriter have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the Underwriter take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. Neither we nor the Underwriter have done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free writing prospectus outside of the United States. 3 PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, especially the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and the related notes included elsewhere in this prospectus. Unless the context otherwise requires, the

View Full Filing

View this S-1 filing on SEC EDGAR